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Abstract
Influenza viruses (IV) cause pneumonia in humans with progression to lung failure and fatal outcome. Dysregulated release
of cytokines including type I interferons (IFNs) has been attributed a crucial role in immune-mediated pulmonary injury
during severe IV infection. Using ex vivo and in vivo IV infection models, we demonstrate that alveolar macrophage (AM)-
expressed IFN-b significantly contributes to IV-induced alveolar epithelial cell (AEC) injury by autocrine induction of the pro-
apoptotic factor TNF-related apoptosis-inducing ligand (TRAIL). Of note, TRAIL was highly upregulated in and released from
AM of patients with pandemic H1N1 IV-induced acute lung injury. Elucidating the cell-specific underlying signalling
pathways revealed that IV infection induced IFN-b release in AM in a protein kinase R- (PKR-) and NF-kB-dependent way.
Bone marrow chimeric mice lacking these signalling mediators in resident and lung-recruited AM and mice subjected to
alveolar neutralization of IFN-b and TRAIL displayed reduced alveolar epithelial cell apoptosis and attenuated lung injury
during severe IV pneumonia. Together, we demonstrate that macrophage-released type I IFNs, apart from their well-known
anti-viral properties, contribute to IV-induced AEC damage and lung injury by autocrine induction of the pro-apoptotic
factor TRAIL. Our data suggest that therapeutic targeting of the macrophage IFN-b-TRAIL axis might represent a promising
strategy to attenuate IV-induced acute lung injury.
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Introduction
Influenza viruses (IV) can cause primary viral pneumonia in
humans with rapid progression to lung failure and fatal outcome
[1]. Histopathologic and clinical features of IV-induced lung injury
in humans resemble those of other forms of ARDS (acute
respiratory distress syndrome), characterized by apoptotic and
necrotic alveolar epithelial cell (AEC) damage, loss of alveolar
barrier function and severe hypoxemia [1–3]. Intrapulmonary
expression of pro-apoptotic ligands such as Fas ligand (FasL) or
TRAIL has recently been ascribed a key role in induction of
epithelial damage during progression to ARDS [4–6]. As soon as
the infection spreads from the upper to the lower respiratory tract,
AEC and resident AM become primary targets for IV infection
[3,7,8]. Severe IV pneumonia is characterized by an exaggerated
alveolar expression of inflammatory mediators and a dysbalance of
pro- and anti-inflammatory cytokines causing pulmonary injury,
and AM have been attributed a substantial role herein [9–11].
However, the key players and molecular mechanisms of the
cellular cross-talk during induction of epithelial injury in severe IV
pneumonia and the inflammatory mediators involved are still
poorly defined. As therapeutic modulation of these pathways offers
the potential advantage of exerting less-selective pressure on viral
populations than established antiviral drugs, a detailed under-
standing of the cell-specific inflammatory responses and subse-
quently induced pathways of epithelial injury in the context of IV
infection is of particular importance.
Type I IFN are rapidly expressed in various myeloid and
parenchymal cell types following viral infection of the lung [12,13].
They engage a unique heterodimeric IFN-a receptor (IFNAR) in
an autocrine or paracrine way to induce the transcription of
various interferon-stimulated genes such as the double-stranded
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(ds) RNA-dependent protein kinase R (PKR) via the Jak/STAT
pathway to restrict viral spread [14,15]. Moreover, type I IFN
signalling was recently ascribed a role in functional differentiation
of myeloid cell subsets during IV infection, including monocytes,
CD8+ T cells, neutrophils and dendritic cells [16–18]. Apart from
these well-known anti-viral effects, evidence also hints at patho-
genic roles for type I IFNs during viral infection. Plenty of pro-
inflammatory cytokines and chemokines are induced downstream
of IFNAR signalling which may contribute to IV pathogenesis,
and disease onset correlates directly with local respiratory
production of IFN-a in humans [19]. Thus, type I IFNs may
play dual roles in viral clearance and tissue-damaging inflamma-
tion.
In the present study we elucidate a previously undefined role of
AM-expressed IFN-b in inducing apoptotic AEC damage by
expression and release of the pro-apoptotic factor TRAIL upon ex
vivo and in vivo IV infection. Detailed study of the signalling
pathways involved in this cellular cross-talk revealed that
macrophage IFN-b was released upon IV infection in a PKR-
and NF-kB-dependent way and induced autocrine, IFNAR-
dependent induction of TRAIL. Macrophage-specific blockade
of any of these signalling steps abrogated TRAIL expression in
resident and lung-recruited AM, reduced AEC apoptosis and
attenuated IV-induced lung injury. These findings highlight type I
IFNs as key players in IV-induced pathogenesis and provide new
insights into the mechanisms of inflammatory macrophage-
epithelial cross-talk in IV-induced lung injury with potential
therapeutic implications.
Results
IV-induced macrophage-derived IFN-b promotes AEC
apoptosis ex vivo and in vivo
To evaluate the role of type I IFN in IV-induced AEC damage
and lung injury, we first quantified type I IFN levels in
bronchoalveolar lavage fluid (BALF) during the time course of
A/PR8 infection in wildtype (wt) mice. As shown in Fig. 1A (left),
IFN-a and -b were both released into the air spaces in response to
A/PR8 infection. Corresponding A/PR8 titers in BALF are
provided (Fig. 1A, right). To test whether endogenous type I IFNs
contributed to the severe lung injury observed in IV-infected mice
we analysed AEC injury after alveolar deposition of a neutralizing
anti-IFN antibody (Ab). As demonstrated in Fig. 1B, AEC
apoptosis was significantly reduced to similar levels when either
IFN-a or IFN-b or both were blocked at d5 pi. In turn, alveolar
injury at d7 pi was further increased when recombinant IFN-b was
applied to the airways of A/PR8-infected mice at d5 pi, as shown
in Fig. 1C (left; AEC apoptosis quantified by AnnexinV binding to
AEC; right, alveolar protein leakage). Of note, lung viral loads at
d7 pi remained unchanged regardless of whether endogenous IFN-
b was blocked or recombinant IFN-b was applied intratracheally
at d5 pi (data not shown). It is well established that AEC and AM
are primary targets for different IV strains in the alveolar
compartment of the lung [20]. To determine the predominant
source of IV-induced alveolar IFN-b, we next infected primary
murine AEC and AM ex vivo with A/PR8 and quantified peak
IFN-b levels in the culture supernatants. Of note, both AEC and
AM were infected by A/PR8 at different MOIs ex vivo as
determined by immunolabelling of viral nucleoprotein (Fig. S1A).
In contrast to AEC, A/PR8 infection of AM was found to be
abortive as we could not detect infectious virions in the
supernatants of AM cultures. As demonstrated in Fig. 1D, murine
AM nevertheless released significantly higher IFN-b levels within
24 h compared to murine AEC in response to infection with live,
but not heat-inactivated A/PR8, and this was similarly found when
we compared human AM and AEC (Fig. S1B). IFN-b expression
robustly occurred in ex vivo IV-infected murine AM in a dose- and
IV strain-dependent manner (Fig. 1E, S2A), and likewise in human
AM (Fig. S2B). To further dissect the mechanisms by which
macrophage IFN-b increased AEC apoptosis, we treated non-
infected AEC with IFN-b ex vivo and determined AEC apoptosis
induction. Interestingly, recombinant IFN-b did not increase
apoptotic damage in infected mono-cultured AEC, however, AEC
apoptosis was highly increased upon IFN-b treatment when AEC
were co-cultured with AM (Fig. 1F). Together, these data indicate
that macrophage IFN-b induces apoptotic AEC damage upon IV
infection and suggest a second, IFN-b-inducible pro-apoptotic
macrophage mediator to be involved.
Macrophage IFN-b induces expression of the pro-
apoptotic factor TRAIL upon IV infection in alveolar
macrophages
Several pro-apoptotic factors are known to induce AEC
apoptosis during pathogen-related acute lung injury, among which
TRAIL and FasL have been reported to be involved [4,5,21]. We
therefore determined whether TRAIL or FasL were upregulated
in murine AM upon ex vivo A/PR8 infection. Whereas FasL gene
and protein expression were less induced (Fig. S3), TRAIL mRNA
was highly upregulated in a dose- and time-dependent manner
after A/PR8 infection in AM, with peak TRAIL expression found
at 16 h pi at an MOI of 1 (Fig. 1G). Furthermore, TRAIL mRNA
was induced after ex vivo infection with different IV strains in
murine AM (Fig. S2C) and, similarly, in human AM (Fig. S2D).
Importantly, TRAIL was increased in alveolar macrophages of
hospitalized patients with pandemic H1N1 (pH1N1)-induced
ARDS as compared to patients with non-viral ARDS or healthy
control individuals, both on mRNA and surface expression level
(Fig. 2A, B). Moreover, soluble TRAIL (sTRAIL) levels were
significantly higher in BALF of pH1N1-ARDS patients compared
to patients suffering from bacterial pneumonia (Fig. 2C), suggest-
ing activation of a TRAIL induction pathway specific for viral
infection. Of note, AEC did not increase TRAIL gene expression
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Figure 1. IV-induced IFN-b is mainly macrophage-derived and induces AEC apoptosis ex vivo and in vivo. (A) C57BL/6 wt mice were
infected with 500 pfu A/PR8 and the IFN-a and IFN-b levels (left panel) as well as the amount of infectious virus particles (right panel) were quantified
from BALF at indicated time points. (B) AEC apoptosis was quantified in mock or A/PR8 infected mice at d7 pi after intratracheal treatment with IgG
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in response to A/PR8 infection to levels observed in murine AM
(Fig. 1H and Fig. S4).
Given the findings that peak TRAIL expression coincided with
peak IFN-b expression at 16 h pi in murine AM (Fig. 1E, G) and
that TRAIL and IFN-b showed similar IV strain-specific induction
patterns in both murine and human AM (Fig. S2), we speculated
that macrophage TRAIL expression was dependent on autocrine
IFN-b-induced signaling. Indeed, when we stimulated non-infected
murine AMwith recombinant IFN-b, we detected a time- and dose-
dependent increase of TRAIL mRNA (Fig. 3A) and significantly
enhanced cell surface TRAIL expression after 24 h of IFN-b
stimulation, which was comparable to A/PR8-induced expression
(Fig. 3B). Finally, blockade of IFN-b-induced signalling via the type
I IFN receptor (IFNAR) nearly abolished A/PR8-induced TRAIL
mRNA upregulation in AM regardless of the MOI applied, as
demonstrated by either addition of neutralizing anti-IFN-b Ab to
the culture medium, use of ifnar2/2 AM, or application of an
inhibitor of the IFNAR downstream mediators, Jak and STAT
(Fig. 3C). Collectively, these data demonstrate that macrophage-
released IFN-b induces expression of the pro-apoptotic factor
TRAIL in AM upon IV infection in an autocrine fashion.
IV-induced IFN-b release and subsequent TRAIL
expression depend on activation of PKR and NF-kB in
alveolar macrophages
Several pattern recognition receptors and downstream signal-
ling events were previously shown to be involved in type I IFN
induction in IV-infected epithelial cells [22,23]. However, the cell-
specific mechanisms of IV recognition and subsequent IFN-b
release in primary AM are far less defined. Given our previous
results on protein kinase R (PKR) as important inflammatory
signal transducer to NF-kB-mediated transcriptional activity in
primary alveolar mouse macrophages [24], we questioned whether
the IV-induced type I IFN response in AM similarly depended on
PKR, known to directly associate with viral RNA in IV-infected
epithelial cells [25]. Indeed, ex vivo A/PR8 infection of murine AM
resulted in phosphorylation of PKR, most prominent at 2–4 h pi
(Fig. 4A). Moreover, the p65 NF-kB subunit was substantially
activated at 4–8 h pi in response to A/PR8 infection in wt but not
pkr2/2 AM (Fig. 4B). Of note, the infection-triggered activation or
expression of transcription factors IRF3 and IRF7, respectively,
known to induce IV-dependent type I IFN responses in epithelial
cells [23,26], did not differ in A/PR8-infected wt and pkr2/2 AM
(Fig. 4C). To test whether the IV-induced type I IFN response in
AM depended on the PKR-NF-kB axis, we quantified IFN-b
release from A/PR8-infected wt vs. pkr2/2 AM or in wt AM after
NF-kB inhibition. As shown in Fig. 4D, both PKR-deficiency and
treatment with a selective IkB kinase (IKK) phosphorylation
inhibitor abrogated IFN-b release in A/PR8-infected AM,
indicating that IV-induced macrophage IFN-b expression re-
quired signal transduction via both PKR and NF-kB. Finally, to
address the significance of this signalling pathway for IV-induced
TRAIL expression in AM, we stimulated wt or pkr2/2 AM with
recombinant IFN-b or infected them with A/PR8 in presence or
absence of the IKK inhibitor with or without neutralizing anti-
isotype Ab, anti IFN-a Ab, anti-IFN-b Ab or both (d5 pi). (C) AEC apoptosis (left panel) and alveolar protein leakage (right panel) were determined at
d7 pi after intratracheal treatment with rIFN-b or vehicle (d5 pi). (D) Murine AEC or AM were mock- or A/PR8-infected (live virus or heat-inactivated) ex
vivo (MOI = 0.1) and IFN-b release was quantified in supernatants at 24 h pi. (E) Murine AM were ex vivo infected with live or heat-inactivated A/PR8 at
the indicated MOI and IFN-b mRNA expression was quantified at the given times and is depicted as fold induction of mock-infected controls. (F)
Uninfected murine AEC were mono- or co-cultured with non-infected AM ex vivo in the presence or absence of IFN-b (180 U/ml) for 24 h, and AEC
apoptosis rates were quantified. (G) Murine AM were ex vivo infected with live or heat-inactivated A/PR8 at the given MOI and TRAIL mRNA
expression was quantified and is depicted as fold induction of mock-infected controls. (H) Murine AEC or AM were ex vivo infected A/PR8 at the
indicated MOI and TRAIL mRNA expression was quantified at the given time and is depicted as fold induction of mock-infected controls. Bar graphs
represent means 6 SD of (A) 4 animals/group, (B, C) 5 animals/group or of 4 (D, E, G) and 3 (F, H) independent experiments. * p,0.05; ** p,0.01;
***p,0.001; ctrl, control; mAEC, murine alveolar epithelial cells; hi, heat inactivated; Ab, antibody, mAM, murine AM; MOI, multiplicity of infection; pi,
post infection; n.s., not significant; iso, isotype; rIFN-b, recombinant IFN-b.
doi:10.1371/journal.ppat.1003188.g001
Figure 2. The pro-apoptotic factor TRAIL is upregulated in alveolar macrophages of patients with severe IV pneumonia. AM were
isolated from BALF of patients with pH1N1-induced ARDS or non-viral (i.e. bacterial pneumonia- or sepsis-associated) ARDS and TRAIL mRNA (A) and
mTRAIL expression (B) were quantified by qRT-PCR and FACS, respectively, and compared to AM of control patients who underwent bronchoscopy
due to diagnostic reasons but revealed normal cell numbers and differential counts (‘healthy’ control). C depicts sTRAIL levels in BALF of patients with
pH1N1-induced ARDS or with confirmed bacterial pneumonia (BP). The graphs show means 6 SD. * p,0.05; ** p,0.01; ***p,0.001; n.s., not
significant; mTRAIL, membrane bound TRAIL; sTRAIL, soluble TRAIL.
doi:10.1371/journal.ppat.1003188.g002
IFN-b Contributes to Influenza-induced Lung Injury
PLOS Pathogens | www.plospathogens.org 4 February 2013 | Volume 9 | Issue 2 | e1003188
Figure 3. IV-induced macrophage IFN-b upregulates macrophage TRAIL. (A) Murine AM were treated ex vivo with rIFN-b at the given
concentrations and TRAIL mRNA expression was quantified and is depicted as fold induction of unstimulated controls. (B) Murine AM were A/PR8-
infected (MOI = 0.1) or treated with 180 U/ml rIFN-b ex vivo in presence of a protease inhibitor cocktail to prevent TRAIL shedding and mTRAIL
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IFN-b Ab. As expected, TRAIL gene expression was significantly
induced upon IFN-b stimulation in both wt and pkr2/2 AM,
regardless of NF-kB inhibition (Fig. 4E, left gray graphs).
However, when AM were A/PR8-infected, TRAIL gene induc-
tion depended on presence of PKR and activation of NF-kB.
Macrophage IFN-b blockade in addition to NF-kB inhibition did
not further decrease TRAIL expression significantly (Fig. 4E, right
black graphs). Altogether, these data demonstrate that IV-infection
of AM induces a PKR-NF-kB-dependent autocrine IFN-b
signaling loop resulting in expression of the pro-apoptotic ligand
TRAIL in IV-infected AM.
The TRAIL receptor DR5 is upregulated in AEC upon IV
infection in an IFN-b-independent manner
To determine whether IV-induced AM-expressed IFN-b might
additionally promote TRAIL-induced signalling on receptor level,
we next quantified AEC TRAIL receptor (DR5, death receptor 5)
expression in mono-cultured AEC. As shown in Fig. 5, DR5 was
abundance was analysed by FACS after 24 h. Shown are histograms from a representative experiment (top panel) or mean fluorescence intensities
(MFI, bottom panel). (C) Murine wt AM were A/PR8 infected at the given MOI and treated with anti-IFN-b Ab, Jak/STAT inhibitor, or DMSO/isotype IgG
Ab as control. Murine ifnar2/2 AM were A/PR8 infected and left untreated. TRAIL mRNA expression was quantified and is depicted as fold induction of
mock-infected cells. Bar graphs represent means 6 SD of (A) 6; (B) 4 and (C) 5 independent experiments. * p,0.05; ** p,0.01; ***p,0.001; MOI,
multiplicity of infection; IgG, IgG isotype control; rIFN-b, recombinant IFN-b; mTRAIL, membrane bound TRAIL; Ab, antibody.
doi:10.1371/journal.ppat.1003188.g003
Figure 4. IV-induced IFN-b release and subsequent TRAIL expression depend on activation of PKR and NF-kB in alveolar
macrophages. (A) Murine AM were A/PR8 infected ex vivo and expression of phosphorylated PKR (p-PKR) and total PKR were assessed by western
blot. Wt or pkr2/2 AM were A/PR8-infected ex vivo and NF-kB p65 activation was comparatively analysed by TransAM assay (quantifying p65 binding
to a consensus-binding site oligo by a colorimetric method) and depicted as fold activation of mock-infected control (B) or phosphorylated IRF-3 in
relation to total IRF-3 protein expression or total IRF-7 expression were determined by western blot at the given time points pi and densitometry data
is depicted as relative expression (C). (D) Wt vs. pkr2/2 AM or IKK inhibitor- vs. DMSO-treated wt AM were A/PR8-infected ex vivo and IFN-b
concentrations in supernatants were analysed 24 h pi. (E) Wt or pkr2/2 AM were either A/PR8-infected or stimulated with 180 U/ml rIFN-b,
respectively, and additionally treated with IKK inhibitor vs. DMSO or anti-IFN-b vs. isotype Ab and TRAIL mRNA expression was quantified 16 h pi. (A)
shows a representative western blot of 3 independent experiments. Bar graphs represent means6 SD of 3 (B, C) or 4 (D, E) independent experiments.
* p,0.05; ** p,0.01; ***p,0.005; ctrl, control; iso, isotype; pi, post infection; Ab, antibody.
doi:10.1371/journal.ppat.1003188.g004
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MOI-dependently upregulated in both murine and human AEC
upon ex vivo A/PR8 infection on gene expression level (Fig. 5A). Of
note, A/PR8-infected (IV nucleoprotein+, NP+) AEC showed
significantly increased DR5 surface expression compared to non-
infected (NP2) AEC within the same culture (Fig. 5B). Interest-
ingly, stimulation of AEC with IFN-b did not impact on DR5 gene
expression (Fig. 5C), and DR5 surface expression on AEC did not
differ between wt and ifnar2/2 mice in vivo (Fig. 5D), suggesting
that macrophage IFN-b induces target cell apoptosis rather by
increased macrophage expression of death receptor ligands than
by affecting DR5 levels on AEC. Nonetheless, IV-infection
sensitizes AEC for TRAIL-mediated killing through IFN-b-
independent DR5 upregulation.
IV-infected alveolar macrophages promote apoptosis in
non-infected and IV-infected AEC in a PKR- and type I
IFN- dependent way by release of sTRAIL
To address whether epithelial IV-infection was required for
macrophage TRAIL-induced apoptosis induction, mock- or A/
PR8-infected AECs were co-cultured with infected AM in the
presence of anti-TRAIL or control IgG isotype Ab. AEC apoptosis
was induced in both mock- and A/PR8-infected co-cultured AEC,
however, apoptosis levels in infected AEC, expressing increased
levels of DR5 (Fig. 5A and B) exceeded those of mock-infected
AEC. Addition of neutralizing anti-TRAIL Ab significantly
reduced AEC apoptosis induction in both mock- or A/PR8-
infected AEC (Fig. 6A). To address whether the macrophage-
specific signalling events mediating IV-induced TRAIL expression
indeed promoted AEC apoptosis, we mock- or A/PR8-infected wt,
pkr2/2, ifnar2/2, or trail2/2 AM for 24 h, co-cultured them with
AEC for further 48 h and then analysed the proportion of
AnnexinV+ AEC. AEC apoptosis rates were not increased upon
co-culture with mock-infected wt, pkr2/2, ifnar2/2, or trail2/2
AM, compared to uninfected, mono-cultured AEC (8.361.8%,
data not shown). However, co-culture with infected wt AM strongly
induced apoptosis in AEC, and this was significantly reduced when
AEC were co-cultured with infected pkr2/2, ifnar2/2,
or trail2/2 AM (Fig. 6B). Similar data were obtained when
expression of cleaved caspase-3 was analysed by western blot in
co-cultured AEC (Fig. 6C). Correspondingly, levels of sTRAIL in
supernatants were significantly increased upon infection of wt, but
not pkr2/2, ifnar2/2, or trail2/2 AM (Fig. 6D). Finally, use of
blocking DR5 Ab and of AEC derived from DR5-deficient mice in
co-cultures revealed that AM-mediated AEC apoptosis induction
was dependent on the epithelial TRAIL receptor DR5 (Fig. 6E).
Collectively, these data demonstrate that PKR-IFN-b/IFNAR-
Figure 5. DR5 is upregulated in AEC upon IV infection in an IFN-b-independent way. (A) Primary murine or human AEC were mock- or A/
PR8-infected ex vivo and DR5 mRNA expression was quantified 48 h pi. (B) Murine AEC were mock- or A/PR8-infected ex vivo and surface DR5
abundance in infected (NP+) vs. non-infected (NP2) AEC from the same culture was analysed by FACS 48 h pi (representative histogram provided in
the left panel) and is depicted as fold MFI (mean fluorescence intensity) of mock-infected cultures (right panel). (C) Murine AEC were stimulated with
rIFN-b or vehicle-treated (ctrl) and DR5 mRNA expression was quantified after 6 h and 12 h and is depicted as DCT values. (D) DR5 surface expression
on AEC from A/PR8-infected wt and ifnar2/2 mice was analysed by FACS. Bar graphs represent means 6 SD of 4 (A) and 5 (B, C) independent
experiments. Bar graphs in D represent means 6 SD of animals/group. * p,0,05; ** p,0,01; ***p,0,001; MOI, multiplicity of infection; hAEC, human
AEC; mAEC, murine AEC; NP, nucleoprotein; iso, isotype Ab; rIFN-b, recombinant IFN-b.
doi:10.1371/journal.ppat.1003188.g005
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dependent macrophage TRAIL- induces apoptotic cell death via
DR5 in both non-infected and IV-infected AEC ex vivo.
Blockade of autocrine myeloid IFN-b signalling
attenuates epithelial injury upon A/PR8 infection in vivo
To investigate whether IFN-b induced pro-apoptotic AM-AEC
cross-talk operates also during in vivo IV infection, A/PR8-infected
wt mice were intratracheally treated with IFN-b at d5 pi. As shown
in Fig. 7A, sTRAIL concentrations in BALF at d7 pi were
significantly increased compared to vehicle-treated or mock-
infected mice. IFN-b-induced (both endogenous and exogenously
applied IFN-b) AEC apoptosis and alveolar protein leakage were
attenuated upon intratracheal treatment with an anti-TRAIL Ab
(Fig. 7B, C). To address the role of PKR activation and subsequent
Figure 6. Macrophage TRAIL induces AEC apoptosis in a PKR- and type I IFN-dependent way ex vivo. (A) 48 h co-cultured murine AEC (mock- or
A/PR8-infected) and AM (A/PR8-infected) were treated with anti-TRAIL or isotype Ab and AEC apoptosis was quantified by flow cytometry (Annexin V staining).
(B, C) Mock- or A/PR8-infected wt, pkr2/2, ifnar2/2 or trail2/2 AM (MOI=0.1) were co-cultured with AEC for 48 h until AEC apoptosis was determined by FACS
(representative FACS plots provided in bottom panel) or western blot using an anti-cleaved caspase-3 Ab and lysates of staurosporin-treated AEC as positive
control. (D) Wt or gene-deficient AMweremock- or A/PR8-infected (MOI=0.1) ex vivo and TRAIL concentrations were determined at 48 h pi. (E) Mock or A/PR8
infected wt macrophages were co-cultured with wt AEC and a neutralizing anti-DR5 antibody or the isotype control were added to the medium. Additionally,
wt mock or A/PR8 infected macrophages were co-cultured with dr52/2 AEC for 48 h and until AEC apoptosis was determined by FACS. (C) shows a
representative western blot of 3 independent experiments. Bar graphs show means 6 SD of (A) 3, (B, D) 5 and (E) 3 independent experiments. * p,0,05; **
p,0,01; ***p,0,001; AM, alveolar macrophages; AEC, alveolar epithelial cells; hi, heat inactivated; ns, not significant; iso, isotype; sTRAIL, soluble TRAIL.
doi:10.1371/journal.ppat.1003188.g006
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type I IFN release in macrophage TRAIL-induced epithelial cell
damage, we next created bone marrow chimeric mice of wt
recipient phenotype which were transplanted wt, pkr2/2, ifnar2/2,
or trail2/2 BM cells. Chimeric mice displayed.90% of circulating
and tissue-resident macrophages of donor phenotype at 12w post
BMT (Fig. S5), and were subjected to A/PR8-infection as outlined
in Fig. 8A. Quantification of sTRAIL in BALF revealed induction
in A/PR8-infected wt BM transplanted mice, whereas sTRAIL
concentrations were significantly reduced in infected chimeric
mice with pkr2/2, ifnar2/2 or trail2/2 AM (Fig. 8B). Likewise, the
proportions of mTRAIL expressing alveolar resident (AM) and
recruited exudate (ExMac) macrophages ranged at ,15% in wt
BM transplanted mice, and were widely reduced when resident or
exudate macrophages were PKR-, or IFNAR-deficient (Fig. 8C,
flow cytometric gating strategies for AM and ExMac depicted in
Fig. S6). Notably, mTRAIL was not significantly expressed on
macrophages of mock-infected mice or on further myeloid lung-
recruited leukocyte populations in BALF (neutrophils; data not
shown) or lung homogenates (CD11b+ dendritic cells, CD103+
dendritic cells; data not shown) in the different groups of chimeric
mice after A/PR8 infection. Correspondingly, the fractions of
apoptotic AEC, increased in A/PR8-infected compared to mock-
infected wt BM transplanted mice, were reduced in mice
transplanted pkr2/2, ifnar2/2 or trail2/2 BM, as demonstrated
by flow cytometric quantification of AnnexinV+ AEC or levels of
cleaved caspase-3 in AEC isolated from mock- or A/PR8-infected
chimeric mice (Fig. 8D, E, respectively). Minor differences in
between the AnnexinV- and cleaved caspase 3-based AEC
apoptosis quantification might result from the analyses of different
signalling events within the apoptotic cascade. Of note, viral
clearance was not affected in mice lacking leukocyte TRAIL or
IFNAR, however, PKR expression in leukocytes was required for
effective antiviral host defense as demonstrated by quantification
of A/PR8 titers in BALF at d7 pi (Fig. S7). Finally, macrophage
TRAIL deficiency was associated with attenuated IV-induced lung
injury and reduced morbidity as shown by alveolar albumin
leakage at d7 pi (Fig. 8F) and body weight loss in the time course pi
(Fig. 8G). Together, these data reveal that TRAIL expression is
induced in a PKR- and type I IFN-dependent way in AM upon
A/PR8 infection in vivo which significantly contributes to IV-
induced lung injury.
Discussion
IV pneumonia is characterized by infection of distal lung
epithelial cells and resident macrophages and frequently progress-
es to acute lung injury/ARDS with poor outcome. Rapid onset of
effective host defense strategies is therefore crucial for recovery
from IV-induced lung damage. On the other side, an exaggerated
inflammatory response will add substantial tissue injury to virus-
induced cytopathic damage. This study elucidates a previously
unrecognized pathway of cytokine-mediated epithelial injury and
highlights the IV-infected alveolar macrophage as key player in
this scenario. We demonstrate that IFN-b, induced in IV-infected
AM through a PKR-NF-kB-dependent pathway, induces expres-
sion and release of the pro-apoptotic ligand TRAIL by autocrine
IFNAR activation, and thereby significantly contributes to IV-
induced apoptotic tissue injury (Fig. 9).
Although it becomes increasingly evident that influenza viral 59-
triphosphate-linked RNA in epithelial cells is primarily recognized
by RIG-I (RNA helicases retinoic acid inducible gene-I) [22], the
pathways of IV-dependent type I IFN induction in primary AM
have not been addressed in this respect. Given that RIG-I-like
helicases signal through the downstream adapter MAVS (mito-
chondrial antiviral signaling, also called IPS-1) in epithelial IV
infection, which mediates IRF3/7-dependent production of type I
IFNs [23], we analysed whether these transcriptional effectors
were required for IFN-b production in primary AM. However, we
did not detect increased expression or activation of IRF7 or IRF3,
respectively, upon A/PR8 infection in wt or pkr2/2 AM. In fact,
our data for the first time demonstrate that, in AM, PKR
signalling and subsequent transcriptional activity of NF-kB are
indispensable for type I IFN release upon IV infection, suggesting
a macrophage-specific way of signal transduction and adding to a
previous study highlighting NF-kB as key regulator of the cellular
type I IFN response towards a highly pathogenic IV [27]. The
importance of macrophage PKR in the context of IV infection is
highlighted by the fact that myeloid PKR-deficiency results in
ineffective viral clearance at d7 pi (Fig. S7). The double-stranded
(ds) RNA-dependent kinase PKR is a well-characterized compo-
nent of the antiviral response present in non-stimulated cells at
basal levels, and further upregulated by type I IFN [15,28]. PKR is
activated by autophosphorylation upon binding to viral RNP
(ribonucleoprotein) complexes and phosphorylates the protein
synthesis eukaryotic initiation factor 2a (eIF-2a), resulting in rapid
inhibition of translation to limit virion production [25,29]. More
recently, PKR was shown to control transcriptional activation of
the NF-kB pathway, independently of its kinase activity, in murine
AM and other cells [24,30]. Whether binding of viral RNPs is
required for NF-kB activation or whether PKR rather transduces
IV-induced upstream signals in AM is under our current
investigation.
Type I IFNs are critical components of the host’s innate
antiviral response [31], and compounds that trigger this response
are clinically in use to treat different viral infections. Accumulating
evidence suggests that engagement of the type I IFN response
prior to infection may be a therapeutic strategy to control IV
infection in different animal models [32,33]. Furthermore, mice
genetically deficient in type I IFN signalling had inefficient IV
clearance [16,34], and ifnar2/2 mice displayed a 50% increased
mortality rate compared to wt litters in response to A/PR8
infection (data not shown). Together with our data obtained from
the ifnar2/2 BM chimeric mouse model, these findings suggests a
minor role of myeloid as opposed to lung parenchymal IFNAR
signalling in antiviral host defense, as ifnar2/2 chimeric mice clear
IV to a similar extent as control mice (Fig. S7). Our data reveal
that AM are a substantial source of IFN-b in the IV-infected lung.
Neutralization of alveolar IFN-b and/or -a at d5 pi attenuated
AEC injury at d7 pi suggesting that blockade of one of the type I
IFNs at the IFNAR receptor is sufficient to strongly reduce AEC
apoptosis. Concomitantly, alveolar deposition of recombinant
IFN-b at d5 pi increased apoptotic AEC injury in IV-infected
lungs, whereas IFN-b pretreatment of mice 24 h prior to infection
significantly reduced viral spread and concomitant alveolar
protein leakage (data not shown). These data add to the
aforementioned studies demonstrating potent anti-viral effects of
IFN-b applied before or early in the infection course and suggest
that a prolonged or exaggerated type I IFN response at later
stages, when virus is virtually cleared from the lungs, might be an
important amplifier of a detrimental inflammatory response in IV
pneumonia.
A major determinant of this interferon-induced detrimental host
response was found to be the potent apoptosis-inducing ligand
TRAIL. TRAIL is a well-characterized component of the host’s
anti-tumour immune response which was thought to exert its pro-
apoptotic effects only towards malignant cells [35]. Only recently,
we and others demonstrated a role of TRAIL-mediated apoptosis
in epithelial injury upon viral pneumonia in mice and humans
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Figure 7. Blockade of IFN-b dependently induced TRAIL attenuates epithelial injury upon IV infection in vivo. (A) A/PR8 infected wt
mice (500 pfu) were intratracheally treated with rIFN-b (10.000 IU) or vehicle (0.1% BSA in PBS) at d5 pi and sTRAIL was quantified from BALF. (B, C) A/
PR8 infected wt mice (500 pfu) were intratracheally treated with rIFN-b or vehicle (0.1% BSA in PBS) and anti-TRAIL Ab or isotype Ab intraperitoneally
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and AEC apoptosis (B) and alveolar protein leakage (C) were determined at d7 pi. Bar graphs show means 6 SD of (A) 6 animals/group and (B, C) 8
animals/group. * p,0,05; ** p,0,01; ***p,0,001. Iso, isotype; sTRAIL, soluble TRAIL; Ab, antibody; pi, post infection.
doi:10.1371/journal.ppat.1003188.g007
Figure 8. Blockade of autocrine myeloid IFN-b signalling impairs macrophage TRAIL expression and attenuates epithelial injury
upon A/PR8 infection in vivo. (A) Treatment protocol: CD45.1+ wt mice were lethally irradiated (6 Gy) and transplanted 16106 CD45.2+ wt, pkr2/2,
ifnar2/2 or trail2/2 BM cells to generate chimeric mice. 12w later, when .90% of AM were of donor (wt, pkr2/2, ifnar2/2 or trail2/2) phenotype,
chimeric mice were mock- or A/PR8-infected and subjected to analyses at 2 d or 7 d pi. (B, C) depict IV-induced sTRAIL concentrations in BALF (B) and
proportions of mTRAIL-expressing AM and ExMac (exudate macrophages) in BALF of chimeric mice at d2 pi (C). (D, E) AEC apoptosis was quantified in
mock- or A/PR8-infected chimeric mice at d7 pi by FACS (D, depicted as Annexin V+ proportion of CD312CD452EpCam+ lung cells, left panel;
representative FACS plots, right panel) or by western blot using lysates of AEC isolated from mock- or A/PR8-infected chimeric mice and a cleaved
caspase-3-specific Ab (E, top panel, western blot of 3 independent experiments; bottom panel, quantification of western blot data by densitometry).
(F) Alveolar albumin leakage was analysed in mock- or A/PR8-infected wt and trail2/2 chimeric mice at d7 pi by intravenous injection of FITC-labelled
albumin and is depicted as ratio of serum and BALF FITC-fluorescence in arbitrary units (AU). (G) Body weight of wt and trail2/2 chimeric mice was
determined post A/PR8 infection (350 pfu/,30%LD50). Bar graphs show means 6 SD of (B, C, D, E, F) 5 animals/group and (G) 8 animals/group. *
p,0,05; ** p,0,01; ***p,0,001; n.d.; not determined; BMT, bone marrow transplantation; dpi, days post infection; pi, post infection; sTRAIL, soluble
TRAIL; mTRAIL, membrane bound TRAIL; Ab, antibody.
doi:10.1371/journal.ppat.1003188.g008
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[5,6]. However the cell-specific signalling events which regulate
TRAIL expression in AM remained elusive. Previous reports
indicated that IFN-b-stimulated dendritic cells engage TRAIL to
mediate tumour cell killing [36] and suggested TRAIL expression
in peripheral blood mononuclear cells to be IFN-dependent [37].
In line with these studies, our data reveal that TRAIL gene
expression is induced by interferon via autocrine IFNAR signalling
in AM upon ex vivo and in vivo IV infection. Importantly, IV strains
of different pathogenicity induced TRAIL gene expression in
murine AM to different extents. The mouse-adapted A/PR8,
known to be highly pathogenic in mice, caused an ,800-fold, and
the highly pathogenic avian H5N1 IV A/Thailand/KAN-1/04,
which causes severe pneumonia in mice [38], induced an ,200-
fold peak increase in TRAIL expression, whereas infection with
the lower pathogenic 631 stimulated by only ,8-fold. Likewise,
patterns of TRAIL mRNA induction resembled those of IFN-b
gene expression. These findings suggest a relation between the
extent of TRAIL-mediated apoptotic AEC injury and the
pathogenic potential of the respective IV strain. Thus, induction
of the type I IFN-TRAIL axis may be considered as novel
determinant of IV pathogenicity. Of note, given our findings that
AM show various levels of permisseveness for different IV strains
(abortive infection of H1N1 IV, high replication rates of highly
pathogenic IV, not shown), the extent by which this pathway
contributes to lung injury upon infection with IV other than A/
PR8 remains to be defined. TRAIL is expressed in a variety of
immune cells such as T cells, NK cells, resident tissue
macrophages, dendritic cells and circulating monocytes [39].
Previous studies demonstrated that antibody-mediated inhibition
of TRAIL signalling resulted in reduced viral clearance in a mouse
model of IV pneumonia [40], and that CD8+ T cells utilize
TRAIL to kill IV-infected alveolar epithelial cells in vivo [41],
suggesting IV-induced TRAIL as important executor of cytotoxic
T lymphocyte (CTL) responses. Although our data obtained from
the BM chimeric mouse model suggest a minor role of leukocyte-
expressed TRAIL in IV clearance, as mice transplanted trail2/2
BM completely cleared IV at d7 pi (Fig. S7), our findings do not
exclude that, apart from FasL or Perforin, antigen-specific CTLs
engage TRAIL to specifically kill infected IV target cells. In
contrast, macrophage TRAIL-mediated epithelial cell killing was
not restricted to IV-infected, DR5 high-expressing AEC, but as
well affected non-infected AEC with low level DR5 surface
expression (Fig. 5, 6). This suggests that TRAIL released from AM
in high amounts upon type I IFN stimulation causes substantial
collateral damage to the (uninfected) epithelial barrier, especially
when macrophages are present in the airspaces in high numbers,
as observed during IV pneumonia [6].
In conclusion, our data reveal a novel role of type I IFNs in
induction of apoptotic alveolar epithelial injury and highlight the
IV-infected macrophage as central player. Identification of the
signalling steps involved in this IFN-b-dependent injurious
macrophage-epithelial cross-talk provides new potential targets
for therapeutic strategies to attenuate lung injury without




All animal experiments were conducted according to the legal
regulations of the German Animal Welfare Act (Tierschutzgesetz)
and approved by the regional authorities of the State of Hesse
Figure 9. Proposed model of IFN-b mediated pro-apoptotic AM-AEC cross-talk in IV-induced lung injury. IFN-b is released from IV-
infected AM in a PKR- and NF-kB-dependent way and induces expression and release of macrophage TRAIL via autocrine IFNAR activation.
Macrophage TRAIL induces AEC apoptosis via its receptor DR5 which is constitutively expressed on non-infected and upregulated on IV-infected AEC.
Through this signalling cascade, IFN-b significantly contributes to AEC damage and lung injury during severe IV pneumonia. IV, influenza virus.
doi:10.1371/journal.ppat.1003188.g009
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(Regierungspra¨sidium Giessen; reference numbers 64/2007, 09/
2009, 39/2011). All experiments were performed under ketamine/
xylazine anesthesia, and all efforts were made to minimize
suffering of infected animals. Human lung tissue was obtained
from patients who underwent lobectomy after informed written
consent (Departments of Pathology and Surgery, Justus-Liebig-
University, Giessen). BALF samples derived from the Universities
of Giessen and Marburg (UGMLC) biobank. Use of human lung
tissue and BALF samples was approved by the University of
Giessen Ethics Committee.
Mice
C57BL/6 wt mice were purchased from Charles River
Laboratories. trail2/2 mice [35] were provided by Amgen Inc.
(Thousand Oaks, CA, USA). pkr2/2 [42] were a kind gift from J.
Pavlovic (Institute of Medical Virology, University of Zurich,
Switzerland). U. Kalinke provided ifnar2/2 mice [43] that under
sponsorship of the Paul-Ehrlich-Institut, Langen, Germany, had
been backcrossed to B6N20. Dr52/2 mice were a kind gift from T.
Mak (Campbell Family Institute for Breast Cancer Research,
Department of Medical Biophysics, University of Toronto,
Canada) [44]. B6.SJL-Ptprca mice expressing the CD45.1 alloan-
tigen (Ly5.1 PTP) on circulating leukocytes (C57BL/6 genetic
background) were obtained from The Jackson Laboratory. Mice
were bred under specific pathogen-free conditions.
Human specimen
Human lung tissue was obtained from lobectomy specimen
distal from tumors. BALF material derived from the Universities of
Giessen and Marburg Lung Center (UGMLC) biobank. BALF
samples from patients who were subjected to bronchoscopy for
diagnostic purposes but displayed normal BALF cellularity and
differential leukocyte counts (i.e. .90% resident alveolar macro-
phages) were used for isolation of resident alveolar macrophages
for in vitro infection experiments or as control samples. pH1N1-
BALF samples were collected from patients admitted to the
Intensive Care Unit of the Department of Internal Medicine II,
UGLC between Dec. 2009 and Jan. 2011 with RT-PCR-
confirmed (BALF) pandemic H1N1 infection (bacterial infection
was excluded in BALF material). All patients (n = 6, age 42615 y)
required mechanical ventilation due to ALI/ARDS and were
subjected to BAL for diagnostic reasons on the day of admission.
BALF material from patients who were mechanically ventilated
due to non-viral (i.e. bacterial pneumonia- or sepsis-induced)
ARDS and samples from patients who were subjected to BAL for
diagnostic reasons at the day of admission and revealed bacterial
pneumonia (n = 8) were additionally included.
Reagents
The following anti-mouse mAbs/secondary reagents were used
for flow cytometry and immunofluorescence: CD31-FITC (BD
Pharmingen, Heidelberg, Germany), CD45-APC-Cy7 (BD Phar-
mingen, Heidelberg, Germany), EpCam-annexin V-Alexa Fluor
647 (Invitrogen, Karlsruhe, Germany), TRAIL (Biolegend,
Uithoorn, Netherlands), IgG2a Isotype (Biolegend, Uithoorn,
Netherlands), donkey anti-rat IgG Alexa Fluor 488 (Invitrogen,
Karlsruhe, Germany), goat anti-rat IgG-PE (Serotec, Du¨sseldorf,
Germany), mouse-anti influenza NP (Meridian life science,
Asbach, Germany), anti-mouse DR5 (R&D, Wiesbaden, Ger-
many), goat anti-mouse IgG Alexa Fluor 647 (Invitrogen,
Karlsruhe, Germany), goat anti-mouse IgG Alexa Fluor 555
(Invitrogen, Karlsruhe, Germany), donkey anti-rat IgG Alexa
Fluor 488 (Invitrogen, Karlsruhe, Germany), CD45.1-FITC (BD
Pharmingen, Heidelberg, Germany), CD45.1-PE (BD Pharmin-
gen, Heidelberg, Germany), CD45.2-APC-Cy7 (Biolegend,
Uithoorn, Netherlands), SiglecF-PE (BD Pharmingen, Heidelberg,
Germany), CD11c-PE-Cy5.5 (Invitrogen, Karlsruhe, Germany),
GR1-PE-Cy7 (Biolegend, Uithoorn, Netherlands), CD3e-APC
(Biolegend, Uithoorn, Netherlands), CD11c-APC (Biolegend,
Uithoorn, Netherlands), MHCII-FITC (BD Pharmingen, Heidel-
berg, Germany), CD103-PE-Cy5.5 (Biolegend, Uithoorn, Nether-
lands), CD11b-PE-Cy7 (Biolegend, Uithoorn, Netherlands), F4/
80-APC (Invitrogen, Karlsruhe, Germany), B220-PE-Cy7 (BD
Pharmingen, Heidelberg, Germany). Anti-human TRAIL-PE and
the corresponding isotype IgG1k-PE were from BD Pharmingen
(Heidelberg, Germany). For western blot analysis the following
anti-mouse antibodies were used: Anti-b-Actin (Biolegend,
Uithoorn, Netherlands), anti-IRF3 (Santa Cruz, Heidelberg,
Germany), anti-phospho IRF3 (Cell Signalling, Frankfurt a.M.,
Germany), anti-IRF7 (Santa Cruz, Heidelberg, Germany), anti-
PKR (Abcam, Cambridge, UK), anti-phospho PKR (Abcam,
Cambridge, UK), anti-cleaved Caspase-3 (Cell Signalling, Frank-
furt a. M., Germany) and secondary anti-rabbit IgG-HRP
antibody (Cell signalling, Frankfurt a. M., Germany). Polyclonal
anti-IFN-b Ab (PBL, Herford, Germany) was used for ex vivo
neutralization at a concentration of 180 IU/ml. For in vivo
neutralization 10.000 IU/70 ml of anti-IFN-a or anti IFN-b Ab
(PBL, Herford, Germany) were intratracheally administered if not
otherwise indicated. The inhibitory anti-TRAIL antibody or
corresponding IgG control (both Biolegend, Uithoorn, Nether-
lands) were used ex vivo at a concentration of 500 ng/ml and
150 mg were intraperitoneally injected at day 3 and 5 post
infection. 10.000 IU/70 ml recombinant murine IFN-b (PBL,
Herford, Germany) diluted in 0.1%BSA or 0.1%BSA alone were
applied intratracheally or added to the cell culture supernatants at
the given concentrations. Recombinant murine TRAIL (R&D,
Wiesbaden, Germany, 100 pg/ml) and Staurosporin (Sigma,
Deisenhofen, Germany, 2 mM) were used for in vitro experiments.
AEC isolation and culture
Murine AEC were isolated by the method developed by Corti
and colleagues [45] as outlined [46]. 2.06105 AEC/well were
seeded in 24 well plates (BD Biosciences, Heidelberg, Germany).
For co-culture experiments, 3.06105AEC were seeded on the
bottom side of 8 mm pore size transwells (BD Biosciences,
Heidelberg, Germany) [47]. The cells were kept in DMEM
supplemented with HEPES, L-glutamine, 10% FCS and antibi-
otics for 5 d. Human AEC were isolated as described previously
[48] and were kept in HAM’s F12 medium (Biochrom, Berlin,
Germany) supplemented with 10% FCS and antibiotics for 5 d.
The purity of murine and human AEC was assessed using anti-
CD45, anti-CD326/EpCam and anti-pro-SP-C antibodies (Biole-
gend, Uithoorn, Netherlands; Millipore, Eschborn, Germany).
Cell suspensions with a purity .90% were used for further
experiments.
Alveolar macrophage isolation and culture
Murine resident alveolar macrophages were isolated by
bronchoalveolar lavage (BALF) from lungs of wt or gene-deficient
mice as described [47], cultivated in RPMI 1640 containing 2%
FCS, L-glutamine and antibiotics and were left to adhere for 2 h
before further treatment. In selected experiments, protease
inhibitor cocktail (1:400 dilution, Sigma, Deisenhofen, Germany)
was added to the culture medium directly after infection or
macrophages were treated with Jak/Stat Inhibitor I (1500 nM in
DMSO, Calbiochem, Darmstadt, Germany) or Bay 11-7082
(25 mM in DMSO, Calbiochem, Darmstadt, Germany) or DMSO
alone was added 1 h prior to and after infection to the cell culture
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medium. In co-culture experiments 2.56105 previously infected or
mock-infected murine resident alveolar macrophages/well were
combined with murine alveolar epithelial cells seeded on the
bottom side of transwells and were co-cultivated for 48 h as
previously described [47].
Human resident alveolar macrophages were purified from
BALF of patients who were subjected to bronchoscopy for
diagnostic purposes but revealed no abnormalities in BALF
cellularity or differential leukocyte counts in BALF and seeded
at a density of 2.56105 cells/well or 1.256105cells/well in a 24- or
48-well plate, respectively. Alveolar macrophages from pandH1N1
or control patients (5.06105 BALF cells/well) were seeded in 12
well plates, kept in RPMI 1640 containing 50% FCS, L-glutamine
and antibiotics and left to adhere for 40 min. Cells were washed
several times to remove non-adherent lymphocytes and neutro-
phils. Macrophage purity was assessed using overall morphological
criteria, including differences in cell size and shape which was
always .90%.
Ex vivo infection
The following IV strains were used for ex vivo infection: A/PR/
8/34 (H1N1) (A/PR8), A/X-31 (H3N2) (631), highly pathogenic
avian H5N1 virus isolated from a human fatal case A/Thailand/
KAN-1/04 (A/Thai) [49], the swine-origin pandemic H1N1 virus
A/Hamburg/5/09 (A/Ham) and seasonal H1N1 virus A/
Memphis/14/96-M (A/Mem) [50]. Heat inactivation was per-
formed at 56uC for 30 minutes. Cells were infected (MOI= 1,
unless otherwise indicated) in a total volume of 75 ml in 48 well
plates or 100 ml in 24well plates diluted in PBS+/+ supplemented
with 0.1% BSA (Sigma, Deisenhofen, Germany) and antibiotics
for 1 h. After removal of the inoculum the respective culture
medium supplemented with 0.1% BSA (Sigma, Deisenhofen,
Germany), 2 mg/ml Trypsin-TPCK (Worthington, Troisdorf,
Germany) and antibiotics was added and cells were incubated at
37uC and 5% CO2 for 16–24 h. For further processing, cells were
trypsinized with Trypsin/EDTA (PAA, Co¨lbe, Germany) for
FACS analyses or lysed for real-time PCR or western blot.
In vivo treatment protocols
Mice were intratracheally inoculated with 350–500 pfu A/PR8
diluted in sterile PBS2/2 in a total volume of 70 ml or mock
infected with PBS2/2 alone. Mice were sacrificed at the indicated
time points and blood and BALF were obtained and handled as
previously described [6]. BALF cells were counted with a
hemocytometer and quantification of leukocyte subsets was
performed by differential cell counts of Pappenheim-stained
cytocentrifuge preparations using overall morphological criteria,
including differences in cell size and shape of nuclei. Alveolar
leakage was analyzed by the lung permeability assay by i.v.
injection of FITC-labelled albumin (Sigma, Deisenhofen, Ger-
many) and detection of FITC-fluorescence in serum and BALF, as
previously described [6] or by detection of total protein
concentrations in BALF by a commercially available spectropho-
tometric assay (BCA assay, Biorad, Mu¨nchen, Germany). For
analysis of AEC apoptosis, lungs were digested by intratracheal
application of Dispase and processed as outlined previously [6].
Creation of bone marrow chimeric mice
BM cells were isolated under sterile conditions from the tibias
and femurs of wt C57BL/6, pkr2/2, ifnar2/2 or trail2/2 donor
mice as previously described after total body irradiation (6 Gy) [6].
As controls for bone marrow engraftment, wt C57BL/6 BM cells
(expressing the CD45.2 alloantigen) were transplanted into
CD45.1 alloantigen-expressing C57BL/6 mice during each
transplantation experiment and the proportion of donor
CD45.2-expressing leukocyte populations in blood, BALF and
lung homogenate were analyzed by flow cytometry. The
proportion of donor circulating and lung-resident myeloid cells
was regularly .90% as shown by FACS analyses of the
proportions of CD45.2+ vs. CD45.2+ cells. Chimeric mice were
housed under specific pathogen free conditions for 12 weeks before
PR/8 infection.
RNA isolation and real time RT-PCR
After cell lysis in RLT buffer (Qiagen, Hilden, Germany), RNA
was isolated using RNeasy mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. For cDNA synthesis,
reagents and incubation steps were performed as outlined
previously [46]. Reactions were performed in a Step one plus
Sequence detection system (Applied Biosystems, Foster City, CA)
using Sybr green as fluorogenic probe in 25 ml reactions
containing 5 ml cDNA sample, Platinum Sybr Green qPCR
supermix (Invitrogen, Karlsruhe, Germany) and 45 pmol of
forward and reverse primer. The following forward and reverse
primers were used: Murine actin forward, 59-ACCCTAAGGC-
CAACCGTGGC-39, reverse 59-CAGAGGCATACAGGGA-
CAGCA-39; human Actin forward, 59-CTGGGAGTGGGTG-
GAGGC-39, reverse 59-TCAACTGGTCtCAAGTCAGTG-39;
murine TRAIL forward, 59-GAAGACCTCAGAAAGTGGC-39
and reverse 59-GACCAGCTCTCCATTCTTA-39; human
TRAIL forward 59-GAGGTTGCAGTGGTGAGA-39, reverse
59-CCCCTGCTGGCAAGTCAA-39; murine IFN-beta 59-ACG-
TCTCCTGGATGAACTCCA-39 and reverse 59-CAGTTGAG-
GACATCTCCCACG-39; human IFN-b forward, 59-CAGCAA-
TTTTCAGTGTCAGAAGC-39, reverse 59-TCATCCTGTCC-
TTGAGGCAGT-39; murine DR5 forward 59-AAGTGTGTC-
TCCAAAACGG-39, and reverse 59-AATGCACAGAGTTCG-
CACT-39; human DR5 forward 59-GGTTCCAGCAAAT-
GAAGGTG-39 and reverse 59-GAGTCAAAGGGCACCAAG-
TC-39. Relative gene abundance to housekeeping gene was
calculated as a DCt value, with DCt=Ct reference2Ct target, and
data are presented as DCT or fold expression (2DDCt) values in
between treatment groups.
Western blot
Cultured cells or AEC isolated from A/PR8 infected mice were
lysed in lysis buffer (20 mM Tris-HCL, 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 0.5% NP-40, 2 mM sodium orthova-
nadate and protease inhibitor cocktail; Roche, Mannheim,
Germany) and the protein content was determined using a
commercially available spectrophotometric assay (BCA assay,
Biorad, Mu¨nchen, Germany). Separation of proteins was resolved
on a SDS-PAGE and transferred onto Hybond PVDF-membrane
(GE healthcare; Mu¨nchen, Germany). Membranes were blocked
and incubated with the primary and secondary antibodies. The
bands were detected using the enhanced chemiluminescent
western blotting system (GE healthcare, Mu¨nchen, Germany).
Viral titers
Virus titers in BALF were determined using plaque assay in
Madin-Darby canine kidney cells. In brief, duplicate cell
monolayers grown in 6-well plates were incubated with 1 ml
BALF dilution for 1 h at room temperature and covered with
1.25% Avicel semi-solid overlay medium containing 2 mg/ml
Trypsin-TPCK (Worthington, Troisdorf, Germany) for 48 h. Cells
were fixed with 4%PFA in PBS, permeabilized with 1%Triton X-
100, incubated with diluted primary anti-NP (Meridian Life
Science, Asbach, Germany) and secondary HRP-conjugated anti-
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mouse antibody (Santa Cruz, Heidelberg, Germany) for 45 min,
respectively, and stained with True Blue (KPL, Gaithersburg, MD,
USA). Plaques were counted using a light microscope (DM 2500,
Leica Microsystems, Wetzlar, Germany).
Flow cytometry
1–56105 cells were washed in FACS buffer (PBS2/2, 7.4%
EDTA, 0.5% FCS, pH 7.2) and fixed in 1%PFA/PBS2/2 or
resuspended in annexin V staining buffer (10 mM HEPES,
140 mM NaCl and 2.5 mM CaCl2), incubated with the respective
primary and secondary antibodies for 15 min at 4uC, and flow
cytometric analysis was performed using a FACSCanto flow
cytometer (BD Biosciences, Heidelberg, Germany) and a FACS
Diva Software.
Immunofluorescence
Cells cultured in chamber slides were fixed for 5 min in a
mixture of methanol:acetone (1:1) and incubated for 30 min in 3%
BSA in PBS. The cells were stained for 2 h with the primary and
after washing for 2 h with the secondary antibody. After a final
washing step the cells were covered with a DAPI-containing
mounting medium (Vectashield; Vector Labs, Eching, Germany)
and left to dry overnight. Samples were analysed with a Leica DM
2000 light microscope using a Leica digital imaging software
(Wetzlar, Germany).
ELISA and TransAM activity assay
Murine and human IFN-a, IFN-b, TRAIL and FasL levels were
analyzed from cell culture supernatants, murine or human BALF
or supernatants of homogenized lungs using commercially
available ELISA Kits (R&D Systems, Wiesbaden, Germany;
PBL, Herford, Germany; USCN, Basel, Switzerland) according
to the manufacturer’s instructions. Activated NF-kB was quanti-
fied using a commercially available TransAM Assay p65 (active
motif, La Hulpe, Belgium) according to the manufacturer’s
instructions. Briefly, the TransAM assay quantifies activated p65
binding to an immobilized consensus-binding site oligo after
addition of nuclear extracts. A primary antibody specific for an
epitope on the bound and active form of p65 is then added
followed by subsequent incubation with secondary antibody and
developing solution for colorimetric quantification.
Statistics
All data are given as mean 6 standard deviation. Statistical
significance between two groups was estimated using the two-tailed
paired or the unpaired student’s t-test for paired or unpaired
samples, respectively. For comparison of.two groups with each
other one-way ANOVA and post-hoc Tukey-HSD was applied.
Significancies were calculated with the SPSS for Windows software
program. A value of p,0.05 was considered as significant.
Supporting Information
Figure S1 A/PR8 infection rates of murine AM and AEC
ex vivo and IFN-b expression in human alveolar
macrophages and epithelial cells upon A/PR8 infection.
(A) Murine AM and AEC were A/PR8 infected with the indicated
MOI and the percentage of NP+ cells was determined at 8 h, 16 h
and 24 h pi. (B) Human AM or AEC were ex vivo A/PR8 infected
using an MOI= 1 and IFN-b mRNA expression was quantified at
the given times and is depicted as fold induction of mock-infected
controls. Bar graphs represent means 6 SD of 4 (A, B)
independent experiments. * p,0.05; ** p,0.01; ***p,0.001.
n.d., not detectable; ns, not significant; AM, alveolar macrophag-
es; AEC, alveolar epithelial cells; pi, post infection; NP,
nucleoprotein; MOI, multiplicity of infection.
(TIF)
Figure S2 IFN-b and TRAIL expression are dependent
on the influenza virus strain in murine and human
alveolar macrophages. Murine (upper and lower left panel) or
human AM (upper and lower right panel) were ex vivo infected with
the indicated IV and MOI and IFN-b (upper left and right panel)
or TRAIL (lower left and right panel) mRNA expression was
quantified at the given times and is depicted as fold induction of
mock-infected controls. Bar graphs represent means 6 SD of (A,
C) n = 3 and (B, D) n= 5 independent experiments. * p,0.05; **
p,0.01; ***p,0.001; mAM, murine AM; hAM, human AM;
MOI, multiplicity of infection; pH1N1, swine originated pandemic
H1N1; sH1N1, seasonal H1N1.
(TIF)
Figure S3 FasL expression in infected alveolar macro-
phages. Murine AM were ex vivo infected with A/PR8 with the
indicated MOI and FasL mRNA expression was quantified at the
given times and is depicted as fold induction of mock-infected
controls (A). Murine AM were ex vivo infected with A/PR8 with the
indicated MOI and sFasL levels were quantified in the cell culture
supernatants (B). Bar graphs represent means 6 SD of 3
independent experiments. * p,0.05; ** p,0.01; ***p,0.001;
MOI, multiplicity of infection, sFasL, soluble Fas Ligand.
(TIF)
Figure S4 Time course of TRAIL expression in IV-
infected AEC. Murine AEC were ex vivo infected with A/PR8 at
the indicated MOI and TRAIL mRNA expression was quantified
at the given times and is depicted as fold induction of mock-
infected controls. Bar graphs represent means 6 SD of 3
independent experiments. * p,0.05; ** p,0.01; ***p,0.001;
MOI, multiplicity of infection; AEC, alveolar epithelial cells.
(TIF)
Figure S5 Efficiency of BM reconstitution and exchange
of resident AM in chimeric mice. To control transplantation
and resident AM reconstitution efficiency in CD45.1+ recipient
mice after BMT with CD45.2+ BM, the fractions of CD45.2+ of
total peripheral blood leukocytes (PBL) and of resident AM were
quantified by flow cytometry from blood or BALF at 12w post
BMT. Bar graphs show means 6 SD from 3 independent
experiments.
(TIF)
Figure S6 Gating strategies for detection of resident AM
and exudate macrophages (ExMac) from BALF. Donor
leukocytes (CD45.2+) were gated on the SSChighCD3e2 fraction to
exclude lymphocytes. Neutrophils were defined as CD11c2GR-
1high (PMN). ExMac were defined as CD11chighSiglecFlowGR-1int
whereas resident AM were defined as CD11chighSiglecFhigh GR-
1low.
(TIFF)
Figure S7 Viral loads in BALF of chimeric wt mice after
transplantation of wt, pkr2/2, ifnar2/2 or trail2/2 BM
at d7 pi. Bar graphs show means of pfu (plaque forming
units)6103 6 SD of 5 animals/group. n.s., not significant.
(TIFF)
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